A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy



Summary

Researchers have developed a lentiviral vector to deliver a neoepitope derived from a common KRAS mutation (G12D) directly to antigen-presenting cells (APCs). This vector encodes the G12D neoepitope fused to calreticulin, enhancing antigen presentation and T-cell activation. In preclinical studies, the vector successfully transduced APCs, leading to robust presentation of the KRAS G12D neoepitope. This induced a strong and specific T-cell response against cells expressing the mutant KRAS protein, demonstrating potential for targeted cancer immunotherapy. The approach aims to overcome limitations of current KRAS-targeted therapies by stimulating a patient’s own immune system to recognize and eliminate cancer cells with this prevalent mutation.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!